Byeong-Suk Chae
Woosuk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Byeong-Suk Chae.
Journal of Ethnopharmacology | 2001
Tae-Yong Shin; Hyun-Ja Jeong; D.K Kim; Sung-Ran Kim; J.K Lee; Byeong-Suk Chae; Jin-Kyung Kim; Hyung-Won Kang; C.M Lee; Kimberly Lee; Sung-Joo Park; Eon-Jeong Lee; Jong-Pil Lim; H.M. Kim; Yun Mi Lee
We investigated the effects of the water soluble fraction of Terminalia chebula (Combretaceae) (WFTC) on systemic and local anaphylaxis. WFTC administered 1h before compound 48/80 injection inhibited compound 48/80-induced anaphylactic shock 100% with doses of 0.01-1.0 g/kg. When WFTC was administered 5 or 10 min after compound 48/80 injection, the mortality also decreased in a dose-dependent manner. Passive cutaneous anaphylaxis was inhibited by 63.5+/-7.8% by oral administration of WFTC (1.0 g/kg). When WFTC was pretreated at concentrations ranging from 0.005 to 1.0 g/kg, the serum histamine levels were reduced in a dose-dependent manner. WFTC (0.01-1.0 mg/ml) also significantly inhibited histamine release from rat peritoneal mast cells (RPMC) by compound 48/80. However, WFTC (1.0 mg/ml) had a significant increasing effect on anti-dinitrophenyl IgE-induced tumor necrosis factor-alpha production from RPMC. These results indicate that WFTC may possess a strong antianaphylactic action.
Experimental Biology and Medicine | 2007
Sang-Yong Kim; Sang-Hyun Kim; Hye-Young Shin; Jong-Pil Lim; Byeong-Suk Chae; Jeong-Suk Park; Seong-Gyun Hong; Myung-Soo Kim; Dong-Gwang Jo; Won-Hwan Park; Tae-Yong Shin
In this study, we investigated the effect of aqueous extract of Prunella vulgaris (Labiatae; PVAE) on the mast cell–mediated allergy model. We found that PVAE (0.001–0.1 g/kg) dose dependently inhibited compound 48/80–induced systemic anaphylaxis and serum histamine release in mice. PVAE decreased the IgE-mediated local allergic reaction, passive cutaneous anaphylaxis. In addition, PVAE attenuated phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187-stimulated TNF-α, IL-6, and IL-8 secretion in human mast cells. The inhibitory effect of PVAE on proinflammatory cytokines was nuclear factor-κB (NF-κB) dependent. PVAE suppressed PMA and A23187-induced NF-κB/DNA binding activity and NF-κB–dependent gene reporter assay. Our findings provide evidence that PVAE inhibits mast cell–derived immediate-type allergic reactions and involvement of proinflammatory cytokines and NF-κB in these effects.
International Journal of Molecular Medicine | 2011
Hui-Hun Kim; Phil Hyung Choi; Jin-Su Yoo; Hoon Jeon; Byeong-Suk Chae; Jeong-Suk Park; Sang-Hyun Kim; Tae-Yong Shin
In this study, we investigated the effect of a water extract of the ripe fruits of Rubus coreanus Miq. (Rosaceae) (RFRC) on mast cell-mediated allergic inflammation and studied the possible mechanism of action. Mast cell-mediated allergic disease is involved in many diseases such as anaphylaxis, rhinitis, asthma and atopic dermatitis. RFRC dose-dependently inhibited compound 48/80-induced systemic anaphylaxis and serum histamine release in mice. RFRC reduced the immunoglobulin E (IgE)-mediated local allergic reaction, passive cutaneous anaphylaxis. RFRC attenuated histamine release from rat peritoneal mast cells and human mast cells by the reduction of intracellular calcium. RFRC decreased the phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore A23187 (PMACI)-stimulated expression and secretion of pro-inflammatory cytokines in human mast cells. The inhibitory effect of RFRC on cytokine production was nuclear factor (NF)-κB- and mitogen-activated protein kinase (MAPK)-dependent. In addition, RFRC suppressed the activation of caspase-1. Our findings provide evidence that RFRC inhibits mast cell-derived allergic inflammatory reactions, and for the involvement of calcium, NF-κB, MAPKs and caspase-1 in these effects. Furthermore, in vivo and in vitro anti-allergic inflammatory effects of RFRC provide affirmative proof of a possible therapeutic application of this agent in allergic inflammatory diseases.
International Immunopharmacology | 2005
Sang-Hyun Kim; Hyo-Hyun Park; Soyoung Lee; Chang-Duk Jun; Byung-Ju Choi; Sang-Yong Kim; Sug-Hyun Kim; Dae-Keun Kim; Jeong-Suk Park; Byeong-Suk Chae; Tae-Yong Shin
Natural product sciences | 2006
Tae-Yong Shin; Hye-Young Shin; Sang-Hyun Kim; Dae-Keun Kim; Byeong-Suk Chae; Chan-Ho Oh; Moon-Gu Cho; Suk-Heung Oh; Jong-Hwa Kim; Tae-Kyoo Lee; Jeong-Suk Park
Natural product sciences | 2009
Hyunjin Lee; Seokwon Yang; Saerom Park; Jae Heon Yang; Byeong-Suk Chae; Jae Soon Eun; Hoon Jeon; Jong Pil Lim; Yong-Hun Hwang; Jong-Han Park; Dae Keun Kim
Natural product sciences | 2006
Tae-Yong Shin; Hye-Young Shin; Sang-Hyun Kim; Dae-Keun Kim; Byeong-Suk Chae; Chan-Ho Oh; Moon-Gu Cho; Suk-Heung Oh; Jong-Hwa Kim; Tae-Kyoo Lee; Jeong-Suk Park; Sang-Yong Kim
Natural product sciences | 2007
Hye-Young Shin; Jong-Pil Lim; Dae-Keun Kim; Byeong-Suk Chae; Young-Ee Kwon; Chan-Ho Oh; Moon-Gu Cho; Tae-Kyoo Lee; Jeong-Suk Park; Jae Hyeok Lee; Hoon Jeon; Tae-Yong Shin
Natural product sciences | 2011
Byeong-Suk Chae
Natural product sciences | 2007
Tae-Yong Shin; Chan-Ho Oh; Dae-Keun Kim; Jae-Soon Eun; Hoon Jeon; Jeong-Suk Park; Myoung-Soon Kim; Jae-Heon Yang; Byeong-Suk Chae